問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Others-

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間:2024-03-26

李重賓Li, Chung-Pin
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -3 個月

篩選

List

171Cases

2023-02-01 - 2026-05-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-07-26 - 2029-10-29

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2015-05-01 - 2020-04-30

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-11-01 - 2025-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated11Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2020-06-01 - 2024-04-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2012-09-02 - 2014-09-18

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-04-27 - 2018-12-31

Phase I

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
  • Condition/Disease

    Gastric Cancer/Esophageal Cancer/Gastro-esophageal Cancer

  • Test Drug

    Oraxol + Ramucirumab

Participate Sites
7Sites

Terminated6Sites

2021-03-01 - 2023-04-15

Phase II

A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Atezolizumab(TecentriqR) Bevacizumab(AvastinR)

Participate Sites
3Sites

Terminated3Sites

2012-09-01 - 2017-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-03-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites